Treatment rooted in tumor biology rather than statistical averages
Each year, tens of thousands of men in the United States learn their prostate cancer has already traveled beyond its origin, forcing an immediate and consequential question: how much treatment is enough, and for whom? A genomic test called Decipher Prostate, validated through the international ENZAMET trial, now offers the clearest answer yet — identifying which men with metastatic disease will genuinely gain years of life from adding chemotherapy to hormone therapy, and which will only gain its burdens. In doing so, it marks a meaningful step in medicine's long effort to treat the individual rather than the average.
- For men with metastatic prostate cancer, the decision to add chemotherapy to hormone therapy has long rested on imprecise risk categories rather than the actual biology of their tumor.
- The ENZAMET trial, analyzing 634 patients over nearly six years, found that men with high Decipher scores and aggressive disease gained measurable survival benefit from triple therapy — while those with lower scores did not, making chemotherapy's toxicity an unnecessary burden for them.
- The statistical interaction between genomic score and treatment response was significant enough to constitute the first level 1B evidence that a genomic test can guide treatment intensification decisions in metastatic prostate cancer.
- A parallel analysis across four major trials showed the test reclassifies roughly one in four high-risk patients, suggesting current clinical guidelines may both over-treat some men and under-treat others.
- The field is now moving toward a model where chemotherapy is prescribed based on tumor gene-expression patterns rather than broad population statistics — a shift that could spare thousands annually from toxicity that would never have helped them.
Every year, roughly 30,000 men in the United States are diagnosed with prostate cancer that has already spread beyond the prostate. For them and their doctors, a critical question arises almost immediately: should chemotherapy be added to hormone therapy, or is hormone therapy alone sufficient? Until recently, that decision has rested on clinical judgment and broad risk categories. A genomic test called Decipher Prostate, developed by Veracyte, now suggests a more precise path.
Researchers presented findings from the ENZAMET trial — a large international randomized study — at the 2026 American Society of Clinical Oncology annual meeting. Analyzing 634 patients over a median follow-up of 5.6 years, the study asked whether Decipher Prostate could predict who would actually benefit from adding the chemotherapy drug docetaxel to standard hormone therapy. The results were clear: men with high Decipher scores and aggressive, high-volume disease saw meaningful survival improvements from triple therapy, while those with lower scores gained nothing from chemotherapy — and faced its toxicity without benefit.
This constitutes the first level 1B evidence — the highest standard in clinical research — that a genomic test can guide treatment intensification decisions in metastatic prostate cancer. The test reads gene-activity patterns in the tumor rather than hunting for specific mutations, capturing something fundamental about how aggressive a cancer truly is. Notably, high-risk patients who received triple therapy achieved survival outcomes comparable to lower-risk patients on two-drug therapy alone, suggesting genomic guidance can help close the gap between aggressive and less aggressive disease.
A separate analysis combining data from four major trials in high-risk localized prostate cancer reinforced the picture: Decipher reclassified roughly one in four patients when integrated with standard clinical risk categories, implying that current guidelines may both over-treat some men and miss others who would benefit from intensification.
For patients, the practical stakes are real. Chemotherapy brings fatigue, neuropathy, infection risk, and lasting quality-of-life consequences. If a genomic test can reliably identify the fraction of men who will actually benefit — while sparing the rest — it moves prostate cancer care meaningfully closer to true precision medicine, where treatment is matched to tumor biology rather than applied uniformly across a risk category.
Every year in the United States, roughly 334,000 men receive a prostate cancer diagnosis. About 30,000 of them face a grimmer reality: their cancer has already spread beyond the prostate. For these men and their doctors, a critical question emerges almost immediately—should chemotherapy be added to hormone therapy, or is hormone therapy alone enough? The answer has never been straightforward. Until now, doctors have relied on clinical judgment and broad risk categories. But a genomic test called Decipher Prostate, developed by Veracyte, suggests there may be a more precise way forward.
The test works by analyzing the genetic signature of a patient's tumor and generating a score that predicts whether that individual will actually benefit from intensified treatment. Researchers presented findings from the ENZAMET trial, a large international randomized study, at the American Society of Clinical Oncology annual meeting in 2026. The analysis examined 634 patients over a median follow-up of 5.6 years, asking a straightforward question: could Decipher Prostate predict who would gain survival benefit from adding the chemotherapy drug docetaxel to standard hormone therapy?
The results were striking in their clarity. Men with high Decipher scores—above 0.85—who also had aggressive, high-volume disease saw a clinically meaningful improvement in survival when given triple therapy (chemotherapy plus two forms of hormone therapy) compared to hormone therapy alone. Those with lower scores, by contrast, showed no survival benefit from chemotherapy. The statistical interaction between the test score and treatment response was significant, meaning the test genuinely predicted who would benefit. Equally important: men with high scores who received triple therapy achieved survival comparable to lower-risk patients treated with just two-drug hormone therapy—suggesting that genomic guidance could help aggressive cancers catch up to less aggressive ones.
This represents the first level 1B evidence—the highest standard of proof in clinical research—that a genomic test can guide decisions about treatment intensification in metastatic prostate cancer. The finding builds on earlier validation from two other major trials, STAMPEDE and CHAARTED, which had already shown Decipher's predictive power in different treatment contexts. The test is a transcriptomic classifier, meaning it reads the activity patterns of genes in the tumor rather than looking for specific mutations. That approach appears to capture something fundamental about how aggressive a cancer truly is.
In a separate analysis presented at the same conference, researchers combined data from four advanced clinical trials examining high-risk localized prostate cancer. Decipher Prostate improved the accuracy of survival predictions compared to using clinical variables alone. The test reclassified roughly one in four patients when integrated with standard risk categories from the National Comprehensive Cancer Network. This matters because it suggests many more high-risk patients might benefit from treatment intensification than current guidelines would identify—but also that some patients currently considered high-risk might safely avoid aggressive therapy.
Christopher Sweeney, the principal investigator from the University of Adelaide's South Australian Immunogenomics Oncology Institute, framed the significance plainly: for the first time, a genomic test had demonstrated it could guide the decision to add chemotherapy to standard hormone treatment in metastatic disease. The test identifies which patients gain from intensification and which can safely forgo chemotherapy. Elai Davicioni, Veracyte's medical director for urology, emphasized that Decipher Prostate is now the most validated transcriptomic test across the entire spectrum of prostate cancer—from active surveillance of early disease through metastatic spread. For doctors, this means clearer answers at each decision point. For patients, it means treatment rooted in the actual biology of their disease rather than statistical averages.
The practical implication is significant. Chemotherapy carries real toxicity—fatigue, neuropathy, infection risk, and quality-of-life impacts. If a genomic test can reliably identify the 30% or 40% of metastatic prostate cancer patients who will actually benefit from it, while sparing the others, that changes the calculus of care. It moves prostate cancer treatment closer to true precision medicine, where therapy is matched to tumor biology rather than applied broadly to all patients in a risk category. For the thousands of men diagnosed with metastatic prostate cancer each year, that distinction could mean the difference between aggressive treatment that extends life and unnecessary toxicity that does not.
Citas Notables
For the first time, a genomic test can guide the decision to add chemotherapy to standard hormone treatment in metastatic prostate cancer— Christopher Sweeney, principal investigator, University of Adelaide
Decipher Prostate identifies which patients benefit from treatment intensification and which can safely forgo chemotherapy, offering doctors an evidence-based answer— Elai Davicioni, Medical Director of Urology, Veracyte
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this test can predict chemotherapy benefit? Couldn't doctors just give everyone chemotherapy and see who responds?
Because chemotherapy is toxic. It causes real harm—nerve damage, infection risk, exhaustion. If you can identify upfront who will actually live longer from it, you spare everyone else from that damage for no benefit.
So the test is saying some patients don't need chemotherapy at all?
Exactly. Men with lower Decipher scores showed no survival gain from adding chemotherapy to hormone therapy. They got the toxicity without the benefit. The test lets doctors avoid that.
What's remarkable about the ENZAMET results specifically?
It's the first high-level evidence that a genomic test can guide this decision in metastatic disease. And it showed something elegant: aggressive cancers with high scores who got triple therapy ended up with survival matching lower-risk patients on two-drug therapy. The test helped aggressive cancers catch up.
How does Decipher actually work? Is it looking for specific mutations?
No, it reads gene activity patterns—the transcriptome. It's measuring how the tumor is behaving at a molecular level, not just looking for a single broken gene. That seems to capture something real about aggressiveness.
The article mentions it reclassified one in four patients. What does that mean practically?
It means a quarter of patients the standard risk categories would label as high-risk actually look different when you add genomic data. Some might not need as much treatment as guidelines suggest. Others might need more. It's more precise sorting.
Is this test available now, or is it still experimental?
Decipher Prostate already exists and is used clinically. These ENZAMET results validate its use in metastatic disease specifically. The test was already validated in earlier trials for other prostate cancer stages.